comparemela.com

Latest Breaking News On - Diabetic macular oedema - Page 1 : comparemela.com

Exonate Ltd.: Exonate Appoints Dr Rafiq Hasan as Non-Executive Director

Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board Exonate Ltd., a biotechnology company developing novel

Rafiq-hasan
Katie-odgaard
Zyme-communications
Exonate-ltd
Complement-therapeutics
Senior-vice-president
Global-head
Clinical-evaluation
New-eyedrop
Alleviating-retinopathy
Diabetic-macular-oedema
Non-executive-director

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director. Rafiq brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.

Exonate-ltd
Complement-therapeutics
Senior-vice-president
Global-head
Clinical-evaluation
New-eyedrop
Alleviating-retinopathy
Diabetic-macular-oedema

EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

EQS-News: Formycon AG / Key word(s): Regulatory Approval/Market Launch FYB201/Ranibizumab keeps gaining momentum with approv.

Algeria
Australia
Jordan
Frankfurt
Brandenburg
Germany
United-states
Alkhars
Ash-sharqiyah
Saudi-arabia
Japan
Switzerland

FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

EQS-News: Formycon AG / Key word: Regulatory Approval/Market Launch FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region 11.03.2024 /.

Alkhars
Ash-sharqiyah
Saudi-arabia
Canada
Amman
O11
Jordan
Frankfurt
Brandenburg
Germany
Japan
Switzerland

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.